Vanda Pharmaceuticals (NASDAQ:VNDA) Announces Quarterly Earnings Results

Vanda Pharmaceuticals (NASDAQ:VNDA) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.31, FiscalAI reports. The company had revenue of $69.81 million during the quarter, compared to analyst estimates of $69.20 million. Vanda Pharmaceuticals had a negative net margin of 119.87% and a negative return on equity of 58.37%.

Here are the key takeaways from Vanda Pharmaceuticals’ conference call:

• Third-quarter revenue rose 24% year over year to $69.8 million, driven by continued FANAPT growth, favorable HETLIOZ shipment timing, and early NEREUS sales. FANAPT prescriptions increased 25% year over year, while NEREUS prescriptions and unique prescribers each more than doubled sequentially.
• Vanda expects to launch BYSANTI in the fourth quarter of 2026, with commercial supplies nearly ready, and is preparing for a potential Quimilza launch in the first half of 2027 if the FDA approves its GPP application by the December 12 PDUFA date.
• Positive Phase III results could expand NEREUS into prevention of GLP-1-associated vomiting and HETLIOZ into delayed sleep-wake phase disorder. Management plans to discuss both programs with the FDA and pursue supplemental applications.
• Operating expenses declined 18% sequentially to $93.3 million as major development and launch-preparation activities concluded, and management expects further reductions in coming quarters.
• Vanda ended September with $140.5 million in cash, down $123.4 million from year-end 2025, and expects 2026 cash burn to exceed 2025 levels. HETLIOZ revenue remains vulnerable to generic competition and specialty-pharmacy inventory normalization, while NEREUS 2026 revenue is expected to remain below $10 million.

Vanda Pharmaceuticals Trading Down 0.5%

Shares of Vanda Pharmaceuticals stock opened at $4.03 on Friday. The company’s fifty day simple moving average is $4.82 and its 200-day simple moving average is $6.23. Vanda Pharmaceuticals has a 1 year low of $3.79 and a 1 year high of $9.94. The company has a current ratio of 1.61, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01. The company has a market cap of $243.65 million, a price-to-earnings ratio of -0.88 and a beta of 0.69.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research report on Monday, October 5th. Zacks Research lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. B. Riley Financial reiterated a “buy” rating and issued a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Thursday, October 15th. Finally, Oppenheimer began coverage on Vanda Pharmaceuticals in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $13.50.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.